open access

Vol 3, No 6 (2007)
Review paper
Published online: 2008-05-08
Get Citation

Consolidation therapy of ovarian cancer

Krzysztof Urbański
Onkol. Prak. Klin 2007;3(6):298-305.

open access

Vol 3, No 6 (2007)
REVIEW ARTICLES
Published online: 2008-05-08

Abstract

Most patients with advanced epithelial ovarian cancer experience objective responses to paclitaxel/platinum- based chemotherapy, but responses are generally short-term and the clinical outcome is still unsatisfactory. Therefore, the strategy to consolidate and to prolong the duration of response is very attractive. Different consolidation or maintenance treatments have been attempted, such as whole abdomen radiotherapy, intraperitoneal chromic phosphate, radioimmunotherapy, intraperitoneal chemotherapy, highdose chemotherapy with haematopoietic support, prolonged administration of the first-line regimen, second- line single-agent chemotherapy, and biological agents. Clinical studies have given conflicting, inconclusive, and generally disappointing results. A recent US randomised trial appeared to show that the prolonged administration of single-agent paclitaxel (175 mg/m2 every 3 weeks) significantly improved the progression-free survival of complete responders to paclitaxel/platinum-based chemotherapy. Alternative less toxic and probably more effective schedules of administration of chemotherapy (i.e. weekly paclitaxel) might assure a better balance between quality of life and anti-tumor activity in patients previously exposed to chemotherapy.

Abstract

Most patients with advanced epithelial ovarian cancer experience objective responses to paclitaxel/platinum- based chemotherapy, but responses are generally short-term and the clinical outcome is still unsatisfactory. Therefore, the strategy to consolidate and to prolong the duration of response is very attractive. Different consolidation or maintenance treatments have been attempted, such as whole abdomen radiotherapy, intraperitoneal chromic phosphate, radioimmunotherapy, intraperitoneal chemotherapy, highdose chemotherapy with haematopoietic support, prolonged administration of the first-line regimen, second- line single-agent chemotherapy, and biological agents. Clinical studies have given conflicting, inconclusive, and generally disappointing results. A recent US randomised trial appeared to show that the prolonged administration of single-agent paclitaxel (175 mg/m2 every 3 weeks) significantly improved the progression-free survival of complete responders to paclitaxel/platinum-based chemotherapy. Alternative less toxic and probably more effective schedules of administration of chemotherapy (i.e. weekly paclitaxel) might assure a better balance between quality of life and anti-tumor activity in patients previously exposed to chemotherapy.
Get Citation

Keywords

ovarian cancer; consolidation therapy

About this article
Title

Consolidation therapy of ovarian cancer

Journal

Oncology in Clinical Practice

Issue

Vol 3, No 6 (2007)

Article type

Review paper

Pages

298-305

Published online

2008-05-08

Bibliographic record

Onkol. Prak. Klin 2007;3(6):298-305.

Keywords

ovarian cancer
consolidation therapy

Authors

Krzysztof Urbański

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl